Analyst: The performance forecast of Novo Nordisk suggests that the average expectations need to be significantly lowered.

Jefferies analysts wrote that the 2026 outlook for Novo Nordisk implies that market average expectations need to be significantly lowered. They added that the new adjusted full-year outlook and management changes will disappoint investors. Sales expectations suggest that market average expectations need to be lowered by a high single-digit percentage, although this may not take into account aggressive assumptions for the oral drug Wegovy. At the same time, the operating profit outlook indicates that market average expectations need to be lowered by a low double-digit percentage. Jefferies stated that as a result, the strong performance in fourth-quarter sales may be overshadowed. US Business Head Dave Moore will leave his position for personal reasons, to be replaced by Jamey Millar from UnitedHealth. Additionally, Head of Product and Product Portfolio Strategy Ludovic Helfgott will leave to seek new opportunities, with Hong Chow from the Merck Group's Health Care division taking over the position. The stock price dropped by 18%.